|
Sign In to gain access to subscriptions and/or personal tools.
|
Aspects of drug development and clinical trials — Part 1
Glenn Matfin
Division of Endocrinology and Diabetes, Department of Medicine, New York University School of Medicine, New York, USA, gnnm{at}novonordisk.com, Novo Nordisk Inc.,100 College Road West Princeton, New Jersey 08540, USA
References
- Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med 2007;356:213-15.[Free Full Text]
- Haslam D., Sattar N., Lean M. ABC of obesity: Obesity-time to wake up. BMJ 2006;333:640-2.[Free Full Text]
- Padwal RS, Majundar SR Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136.[Free Full Text]
- Nathan DM, Davidson M., DeFronzo RA et al. Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for Care. A Consensus Statement from the American Diabetes Association. Diabetes Care 2007;30:753-9.[Free Full Text]
- Alberti Kgmm, Zimmet P., Shaw J. International Diabetes Federation (IDF): a consensus on type 2 diabetes prevention. Diabet Med 2007;24:451-63.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ 2006;333:475-80.[Free Full Text]
The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 3,
97-98 (2007)
DOI: 10.1177/14746514070070030101

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|